Overcoming Resistance Against HER2-Targeting Agents in Fifth-Line Therapy: Is There Still a Place for Bevacizumab in HER2+ Breast Cancer?

Overcoming Resistance Against HER2-Targeting Agents in Fifth-Line Therapy: Is There Still a Place for Bevacizumab in HER2+ Breast Cancer?

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Breast Cancer - Volume 14, Issue 1, February 2014, Pages e17-e20

Florian Huemer, Simon Peter Gampenrieder, Alexander Schlattau, Richard Greil,